Altmetric

The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines

File Description SizeFormat 
JHI-D-18-00499_R1.pdfAccepted version8.41 MBAdobe PDFView/Open
Title: The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines
Authors: Mullish, BH
Quraishi, MN
Segal, JP
McCune, VL
Baxter, M
Marsden, GL
Moore, D
Colville, A
Bhala, N
Iqbal, TH
Settle, C
Kontkowski, G
Hart, AL
Hawkey, PM
Williams, HRT
Goldenberg, SD
Item Type: Journal Article
Abstract: Interest in the therapeutic potential of faecal microbiota transplant (FMT) has been increasing globally in recent years, particularly as a result of randomised studies in which it has been used as an intervention. The main focus of these studies has been the treatment of recurrent or refractory Clostridium difficile infection (CDI), but there is also an emerging evidence base regarding potential applications in non-CDI settings. The key clinical stakeholders for the provision and governance of FMT services in the United Kingdom (UK) have tended to be in two major specialty areas: gastroenterology and microbiology/infectious diseases. While the National Institute for Health and Care Excellence (NICE) guidance (2014) for use of FMT for recurrent or refractory CDI has become accepted in the UK, clear evidence-based UK guidelines for FMT have been lacking. This resulted in discussions between the British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS), and a joint BSG/HIS FMT working group was established. This guideline document is the culmination of that joint dialogue.
Issue Date: 1-Sep-2018
Date of Acceptance: 24-Jul-2018
URI: http://hdl.handle.net/10044/1/62909
DOI: https://dx.doi.org/10.1016/j.jhin.2018.07.037
ISSN: 0195-6701
Publisher: WB Saunders
Start Page: S1
End Page: S31
Journal / Book Title: Journal of Hospital Infection
Volume: 100
Issue: Supplement 1
Copyright Statement: © 2018 The Healthcare Infection Society. Published by Elsevier Ltd. All rights reserved. This manuscript is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Licence http://creativecommons.org/licenses/by-nc-nd/4.0/
Sponsor/Funder: Imperial College Healthcare NHS Trust- BRC Funding
Imperial College Healthcare NHS Trust- BRC Funding
Medical Research Council
Medical Research Council (MRC)
Funder's Grant Number: RDA27
RDA02
MR/R00875/1
MR/R000875/1
Keywords: Science & Technology
Life Sciences & Biomedicine
Public, Environmental & Occupational Health
Infectious Diseases
microbiota
faecal transplant
Clostridium difficile
inflammatory bowel disease
INFLAMMATORY-BOWEL-DISEASE
RANDOMIZED CLINICAL-TRIAL
TERM-FOLLOW-UP
PUMP INHIBITOR THERAPY
ACTIVE ULCERATIVE-COLITIS
INTESTINAL MICROBIOTA
GUT MICROBIOTA
CASE SERIES
OPEN-LABEL
COST-EFFECTIVENESS
1103 Clinical Sciences
Epidemiology
Publication Status: Published
Online Publication Date: 2018-08-31
Appears in Collections:Division of Surgery
Department of Medicine
Faculty of Medicine



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Creative Commons